Adepa

Adepa is an Australian biotech unlocking the unrealised potential of branched fats, a previously overlooked early-life nutrient, to support gut, brain, and skin health. Our technology pioneers a new class of stable medical nutrition ingredients designed for real-world use by consumers and brands.    

Born from neonatal research at Cornell University in the United States and the clinical experience of our founders, Adepa is grounded in science and has already served over 20,000 customers. Our sole flagship product, ‘Daily Peribiotics’, is sold Direct-to-Consumer, generating over $70,000 per month in sales, cash-flow positive, clinically validated in IBS, and supported by hundreds of 5-Star reviews.

Following the success and demand of Daily Peribiotics, Adepa is raising funds to expand into children’s health, pet nutrition, and skincare, while increasing production to enhance real-world probiotic efficacy and establish a new class of gut health solutions.

By investing in Adepa, you are backing a proven team, a patented technology platform, and a first-mover position in an $84B market.

Reasons to Invest

• Clinically validated product: Probiotics fail to work for 60 - 80% of users. Adepa’s ‘Daily Peribiotics’ has shown increased efficacy in managing IBS symptoms.
• Exclusive, IP-backed technology based on branched fats licensed from Cornell University, USA.
• Generating $70,000 in sales per month.
• Cash flow positive since June 2025, with over 20,000+ customers served.
• First-mover advantage in a wide-open category with low consumer awareness and no direct competition.
• Led by world experts in fatty acid nutrition with a track record in commercialisation.
• Upcoming product launches in kids, pet and skincare health.
• Featured in major outlets like WIN News, Channel 9, 2GB Sydney, MSN, the Illawarra Mercury and New Nutrition Business Journal.
• Positioned in a rapidly growing probiotics market, valued at $84B USD.

  
  

Opportunity

Branched fats are a scientifically validated but commercially overlooked nutrient found in healthy early-life biology. These compounds resemble those found in vernix caseosa and breast milk, where they support gut cells and healthy microbial ecosystems.

Our flagship innovation is produced using our proprietary Bacillus subtilis BG01-4™ strain, selected for its exceptionally high branched fat levels; the secret ingredient behind thousands of happy Adepa customers. 

Protected by exclusive IP from Cornell University,  and developed with QUT and La Trobe University, our clinically-validated product is heat-stable and provides a superior nutrient for consumers and infant formula and medical food brands.

With only a handful of players even aware of this science, Adepa has a first-mover advantage that unlocks their power to improve gut health, nutrition and the efficacy of existing probiotic products.

The Problem

More than 60% of people suffer from gut discomfort, digestive irregularity or chronic conditions linked to microbiome imbalance. Today, consumers and brands have turned to probiotics as the solution. Yet, it turns out only 20-40% of probiotics are efficacious, and less than 15% of infant formulas can use probiotics due to safety and stability issues.

Despite booming sales, the industry delivers limited real-world outcomes. Probiotic strains struggle to survive, colonise or adapt to individual variability, leaving a huge gap between spend and success.

The Solution

Our proprietary Bacillus subtilis BG01-4™ has been shown in early clinical research to increase probiotic efficacy and convert many non-responders into responders, creating a breakthrough ingredient that helps improve results in existing gut health products. 

Stable and Versatile: Heat-resistant and shelf-stable, suitable for infant formula, medical foods, supplements, skincare, and pet health.

Cost-effective: Lower COGS compared with probiotics while delivering superior results.

Clinically-validated: Recent randomised, double-blind, placebo-controlled clinical trials  (published in Nutrients, Oct 2023) showed significant improvements in IBS & gastrointestinal symptoms:

• > 30% improvement in constipation vs placebo.
• Significant improvement in indigestion + dyspepsia.
• Better overall GSRS gut symptom scores.
• Natural branched fats support both gut cells + microbiome balance.

Unlike probiotics, they are shelf-stable and heat-resistant, enabling broader application in everything from infant formula to supplements, skincare and pet health.

Team & Company Structure

Adepa is led by co-founders Professor Tom Brenna and Dr Craig Patch.

Professor Brenna is a globally recognised expert in fatty acid biology, a professor at the University of Texas and a former FDA and WHO advisor. His research shaped DHA (a blockbuster fatty acid ingredient) regulations for infant formula and established the scientific basis for branched fats.

He has received major international nutrition awards (Osborne and Mendel Award for basic research and the Robert Herman Award for clinical nutrition), and co-authored best-practice guidelines that define how fatty-acid clinical studies are designed and analysed, giving the company direct access to the scientist who co-invented and clinically validated its core branched-fat platform.​

Dr Craig Patch is a nutrition scientist and former Chief Innovation Officer at Clover Corporation. He holds a PhD in Biomedical Science, an MBA and nutrition & dietetics, and is recognised as a thought leader in translating fatty‑acid and microbiome science into scalable products and value-added supply chains. With 30+ years in biomedical science and product commercialisation, he has launched multiple ventures and led the development of specialty nutrition programs in gut and early-life health.

Adepa is supported by key research and supply partners, including QUT, La Trobe University and Biomecentric.

Business Model

Adepa operates a direct-to-consumer e-commerce model and select distributors in NZ, MLB, and Townsville. Revenue is generated from sales of Daily Peribiotic, our clinically validated IBS supplement.

With over 7,000 subscribers, strong customer retention and monthly revenue in excess of $70,000, Adepa is preparing to launch three new products in the infant, pet and skincare markets. This product diversification and IP protection enable recurring and scalable revenue growth across multiple consumer categories.

Use of Funds

Funds raised will be allocated to:

• Scaling inventory to meet growing demand for Daily Peribiotics.
• Launching 3 new products across children’s gut health, pet nutrition and skincare.
• Strengthening marketing and e-commerce operations.
• Supporting continued clinical research and product validation.

This capital injection will allow Adepa to maximise first-mover advantage and capitalise on the growing awareness of gut health and functional nutrition.

Risks

Like all early-stage investments, Adepa presents certain risks, including:

• Market Risk: Consumer preferences and regulatory changes could impact growth.
• Operational Risk: Scaling inventory and managing multiple product launches simultaneously.
• Competitive Risk: Entry of larger players into the branched fat category.

Adepa has already successfully defended the patents from a challenge by Nutricia Europe and is mitigating risks through strong IP protection, expert leadership, and a focused go-to-market strategy aligned with scientific validation.

About Swarmer

Swarmer is an Australian equity crowdfunding platform connecting businesses and investors. Designed to support start-ups, growth companies and scale-ups we allow everyday investors to own a share in businesses that are the future. We hold Australian Financial Services License (AFS License #507867). 

Find out more about becoming a shareholder via Equity Crowdfunding through Swarmer.